China News Service, Guangzhou, April 9 (Cai Minjie), a data and information service platform in the medical and health field, Minnet.com, announced on the 9th that the scale of China's pharmaceutical terminal market in 2019 was 1,795.5 billion yuan, an increase of 4.8% year-on-year. The growth rate of the Chinese patent medicine market is weak. However, Zhang Buyong, general manager of Minnet.com, believes that due to the impact of the new coronary pneumonia epidemic, the share of Chinese patent medicine in medical institutions is expected to increase.
"In 2018, China's three major terminal drug sales reached 1,711.3 billion yuan, an increase of 6.3% year-on-year." Zhang Buyong, general manager of Minet.com, said that based on the average retail price of drugs in the three major terminals, the terminal drug sales in 2019 Increased by 4.8% year-on-year in 2018, and the growth rate further slowed down. There are many reasons for the slowdown, including the continued slowdown in the growth rate of the generic drug market, the weak growth rate of the Chinese patent medicine market, and the overall scale of innovative drugs is still small and the growth rate Limited contribution etc.
In the Chinese patent medicine market, according to data from Minet.com, all Chinese patent medicine terminal sales reached more than 300 billion yuan in 2019, accounting for more than 21% of the total medical terminal sales of public medical institutions at 137.59 billion yuan, which are normally sold in public medical institutions. There are 19,618 regulations for Chinese medicines, which is an important area.
Zhang Buyong said that since 2018, many provinces across the country have issued relevant policies stating that key supplementary medicines should be supervised or restricted to use. There are many well-known large varieties of traditional Chinese medicine. The key monitoring of supplementary medicine by medical institutions across the country is one of the reasons for the slow growth of the Chinese patent medicine market. Therefore, the growth rate of Chinese patent medicine in hospitals has gradually slowed in recent years, and there has been basically no growth in 2019 compared with 2018.
"During the outbreak and epidemic of the new coronary pneumonia, Chinese medicine control and treatment-related symptoms have been recognized by the pharmaceutical industry and society. At present, some provinces and cities have also introduced basic medical insurance to support the implementation of innovative development of traditional Chinese medicine. The payment for special diseases and the tilt towards medical insurance settlement for TCM hospitals. "Zhang Buyong believes that the impact of the epidemic will increase the share of Chinese patent medicine in medical institutions.
In terms of innovative drugs, according to data from Minet.com, monoclonal antibodies and protein kinase inhibitors (mainly tinib antitumor drugs) total only about 40 billion yuan, plus the total amount of new drugs approved in the past two decades is insufficient 100 billion yuan, only accounted for about 7.3% of the total medical terminal sales of 1,375.9 billion yuan in public medical institutions.
"Innovative drugs will be the growth point for the future development of the pharmaceutical industry, and the market share and growth rate of innovative drugs will be accelerated, but from the perspective of current terminal market sales, the overall terminal scale of innovative drugs accounts for the drug data of the entire public medical institutions. It's still very small, "Zhang Buyong said. (Finish)